Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab versus off-label rituximab at onset of relapsing-remitting multiple sclerosis
2020-001205-23Phase 3Active
- Sponsor
- Helse Bergen
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple sclerosis (MS) comparing Ocrelizumab arm with Rituximab arm (2 arms). Primary endpoint: Primary efficacy and safety comparison. Started Jun 2020; status: active.
02
Drugs
ocrelizumabrituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2020-001205-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001205-23.